Advancing precision medicine through next-gen liquid biopsy platform

Molecular insights into cancer from blood or urine to enable precision medicine.

Predicine workflow

Cell-free cancer
biology

Analyze fragments of DNA and RNA circulating in blood and urine

Breakthrough AI-driven bioinformatics

Unlock complex genomic data for precision medicine

Powerful data to advance precision medicine

Decipher cancer genome to accelerate oncology drug development

The Predicine Advantage

Comprehensive molecular profiling

cfDNA and cfRNA liquid biopsy tests using blood

LEARN MORE

Urine molecular diagnostics

Ideal for bladder cancer – more robust variant detection than blood

LEARN MORE

Ultra-sensitive variant detection

cfDNA mono- vs bi-allelic gene deletion and low input profiling (<4mL plasma)

LEARN MORE

End-to-end clinical lab solutions

CLIA and CAP labs in U.S. and China to support global studies

LEARN MORE

Generadar

Unprecedented, comprehensive cancer profiling

Disease and functional biology-focused liquid biopsy: DNA + RNA

Genomic assays built on Predicine’s proprietary GeneRADAR next generation liquid biopsy platform and DeepSEA machine learning platform. It measures cancer-associated genomic blueprint (DNA) and functional biology (RNA) in a single tube of blood sample.

Urine-based Liquid biopsy

Urine: Painless cancer detection

Fast, easy, and truly non-invasive.

Predicine introduces urine-based liquid biopsy to broaden cancer patients’ access to genomic profiling. Urine-based cfDNA can be more robust in variant detection than blood-based cfDNA in genitourinary cancers. 

“Liquid biopsy is the future of precision medicine. Our work with Predicine’s liquid biopsy platform is very encouraging for the field of liquid biopsy and supports its clinical application for patient care.”

Massimo Cristofanilli, M.D.
Professor of Northwestern University and President of International Society of Liquid Biopsy

Partnerships

Unified biomarker solutions for global clinical trials

End-to-end clinical lab solutions in U.S. and China

Through our network of CLIA/CAP certified facilities in California and Shanghai, Predicine partners with leading biopharmaceutical companies to support biomarker-driven global ­­clinical trials.

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your info via the form below and we will respond within 24 hours.